US Biosimilars Market - 2025-2033
US Biosimilars Market reached US$ 8.62 billion in 2024 and is expected to reach US$ 65.62 billion by 2033, growing with a CAGR of 25.50% during the forecast period 2026-2033.
The US Biosimilars Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A US Biosimilars Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product Type
Both primary and secondary data sources have been used in the global US Biosimilars Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The US Biosimilars Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A US Biosimilars Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Product Type
- Monoclonal Antibodies*
- Recombinant Human Growth Hormone (rhGH)
- Insulin
- Anti-coagulants
- Erythropoietin
- Granulocyte Colony Stimulating Factor
- Follitropin
- Interferons
- Others
- Oncology*
- Chronic Diseases
- Autoimmune Diseases
- Infectious Diseases
- Growth Hormone Deficiency
- Hematology
- Others
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global US Biosimilars Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Number of FDA Approved Biosimilars
3.1.1.2. Strong Pipeline of Biosimilars in Development
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Lack of Physician and Patient Awareness
3.1.2.2. Immunogenicity and Safety Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Expansion of Biosimilars for Various Applications
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Product
4.2. Latest Developments and Breakthroughs
4.3. US Regulatory and Reimbursement Landscape
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. SWOT Analysis
4.7. Pipeline Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.11. Pricing Analysis and Price Dynamics
4.12. Key Opinion Leaders
5. BIOSIMILARS MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Monoclonal Antibodies*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Recombinant Human Growth Hormone (rhGH)
5.4. Insulin
5.5. Anti-coagulants
5.6. Erythropoietin
5.7. Granulocyte Colony Stimulating Factor
5.8. Follitropin
5.9. Interferons
5.10. Others
6. BIOSIMILARS MARKET, BY APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Chronic Diseases
6.4. Autoimmune Diseases
6.5. Infectious Diseases
6.6. Growth Hormone Deficiency
6.7. Hematology
6.8. Others
7. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
7.1. Competitive Overview and Key Market Players
7.2. Market Share Analysis and Positioning Matrix
7.3. Strategic Partnerships, Mergers & Acquisitions
7.4. Key Developments in Product Portfolios and Innovations
7.5. Company Benchmarking
8. COMPANY PROFILES
8.1. Amgen Inc.*
8.1.1. Company Overview
8.1.2. Product Portfolio
8.1.2.1. Product Description
8.1.2.2. Product Key Performance Indicators (KPIs)
8.1.2.3. Historic and Forecasted Product Sales
8.1.2.4. Product Sales Volume
8.1.3. Financial Overview
8.1.3.1. Company Revenue’s
8.1.3.2. Geographical Revenue Shares
8.1.3.3. Revenue Forecasts
8.1.4. Key Developments
8.1.4.1. Mergers & Acquisitions
8.1.4.2. Key Product Development Activities
8.1.4.3. Regulatory Approvals, etc.
8.1.4.4. SWOT Analysis
8.2. Pfizer Inc.
8.3. Sandoz Group AG
8.4. Teva Pharmaceuticals USA, Inc.
8.5. Biogen
8.6. Biocon Biologics Inc.
8.7. Boehringer Ingelheim International GmbH
8.8. Samsung Biologics
8.9. Dr. Reddy’s Laboratories Ltd.
8.10. Fresenius Kabi USA, LLCLIST NOT EXHAUSTIVE
9. ASSUMPTION AND RESEARCH METHODOLOGY
9.1. Data Collection Methods
9.2. Data Triangulation
9.3. Forecasting Techniques
9.4. Data Verification and Validation
10. APPENDIX
10.1. About Us and Services
10.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Number of FDA Approved Biosimilars
3.1.1.2. Strong Pipeline of Biosimilars in Development
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Lack of Physician and Patient Awareness
3.1.2.2. Immunogenicity and Safety Concerns
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Expansion of Biosimilars for Various Applications
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Product
4.2. Latest Developments and Breakthroughs
4.3. US Regulatory and Reimbursement Landscape
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. SWOT Analysis
4.7. Pipeline Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.11. Pricing Analysis and Price Dynamics
4.12. Key Opinion Leaders
5. BIOSIMILARS MARKET, BY PRODUCT TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
5.1.2. Market Attractiveness Index, By Product Type
5.2. Monoclonal Antibodies*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Recombinant Human Growth Hormone (rhGH)
5.4. Insulin
5.5. Anti-coagulants
5.6. Erythropoietin
5.7. Granulocyte Colony Stimulating Factor
5.8. Follitropin
5.9. Interferons
5.10. Others
6. BIOSIMILARS MARKET, BY APPLICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
6.1.2. Market Attractiveness Index, By Application
6.2. Oncology*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Chronic Diseases
6.4. Autoimmune Diseases
6.5. Infectious Diseases
6.6. Growth Hormone Deficiency
6.7. Hematology
6.8. Others
7. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
7.1. Competitive Overview and Key Market Players
7.2. Market Share Analysis and Positioning Matrix
7.3. Strategic Partnerships, Mergers & Acquisitions
7.4. Key Developments in Product Portfolios and Innovations
7.5. Company Benchmarking
8. COMPANY PROFILES
8.1. Amgen Inc.*
8.1.1. Company Overview
8.1.2. Product Portfolio
8.1.2.1. Product Description
8.1.2.2. Product Key Performance Indicators (KPIs)
8.1.2.3. Historic and Forecasted Product Sales
8.1.2.4. Product Sales Volume
8.1.3. Financial Overview
8.1.3.1. Company Revenue’s
8.1.3.2. Geographical Revenue Shares
8.1.3.3. Revenue Forecasts
8.1.4. Key Developments
8.1.4.1. Mergers & Acquisitions
8.1.4.2. Key Product Development Activities
8.1.4.3. Regulatory Approvals, etc.
8.1.4.4. SWOT Analysis
8.2. Pfizer Inc.
8.3. Sandoz Group AG
8.4. Teva Pharmaceuticals USA, Inc.
8.5. Biogen
8.6. Biocon Biologics Inc.
8.7. Boehringer Ingelheim International GmbH
8.8. Samsung Biologics
8.9. Dr. Reddy’s Laboratories Ltd.
8.10. Fresenius Kabi USA, LLCLIST NOT EXHAUSTIVE
9. ASSUMPTION AND RESEARCH METHODOLOGY
9.1. Data Collection Methods
9.2. Data Triangulation
9.3. Forecasting Techniques
9.4. Data Verification and Validation
10. APPENDIX
10.1. About Us and Services
10.2. Contact Us
